Catalog No.
DHJ80302
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
KIAA1194, CCR4, CNOT6, CCR4a, CCR4 carbon catabolite repression 4-like, Cytoplasmic deadenylase, Carbon catabolite repressor protein 4 homolog, CCR4-NOT transcription complex subunit 6
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9ULM6
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
AT008
Clone ID
AT008
Note
For research use only. Not suitable for clinical or therapeutic use.
CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model., PMID:37157185
Mogamulizumab for Treatment of Human T-lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis: A Single-Center US-based Series., PMID:37157862
Circulating Regulatory T Cell Subsets in Patients with Sarcoidosis., PMID:37189479
Recruitment of regulatory T cells with rCCL17 promotes M2 microglia/macrophage polarization through TGFβ/TGFβR/Smad2/3 pathway in a mouse model of intracerebral hemorrhage., PMID:37257716
Lung group 2 innate lymphoid cells differentially depend on local IL-7 for their distribution, activation, and maintenance in innate and adaptive immunity-mediated airway inflammation., PMID:37493250
CCR4 predicts the efficacy of abatacept in rheumatoid arthritis patients through the estimation of Th17 and Treg cell abundance., PMID:37522614
Targeting Members of the Chemokine Family as a Novel Approach to Treating Neuropathic Pain., PMID:37570736
Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors., PMID:37729184
Targeting Monocyte Derived CCL17 Attenuates Murine Crescentic Glomerulonephritis by Affecting Renal CCR4+ Regulatory T-Cell Recruitment., PMID:37742620
Circulating CD8+ T Cell Subsets in Primary Sjögren's Syndrome., PMID:37893153
Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas., PMID:37998391
High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy., PMID:38016720
Nickel Challenge In Vitro Affects CD38 and HLA-DR Expression in T Cell Subpopulations from the Blood of Patients with Nickel Allergy., PMID:38203472
Development of Innate-Immune-Cell-Based Immunotherapy for Adult T-Cell Leukemia-Lymphoma., PMID:38247820
Targeting CCR4 with mogamulizumab in refractory CD3-CD4+ lymphocytic-variant hypereosinophilic syndrome., PMID:38328856
Dynamics of Whole Transcriptome Analysis (WTA) and Surface markers expression (AbSeq) in Immune Cells of COVID-19 Patients and Recovered captured through Single Cell Genomics., PMID:38357647
Toxicology, pharmacokinetics, and immunogenicity studies of CCR4-IL2 bispecific immunotoxin in rats and minipigs., PMID:38367684
Failure of second challenge with mogamulizumab in C-C chemokine receptor 4-positive cutaneous T-cell lymphoma., PMID:38390970
Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review., PMID:38396877
An occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report., PMID:38456078
Unleashed monocytic engagement in Sézary syndrome during the combination of anti-CCR4 antibody with type I interferon., PMID:38489234
Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis., PMID:38532079
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study., PMID:38547425
The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab., PMID:38703428
Fatal acute graft-versus-host disease in Sézary Syndrome treated with Mogamulizumab and hematopoietic cell transplantation., PMID:38718540
Fulminant hepatitis in a hepatitis B surface antigen-positive patient with adult T-cell leukemia-lymphoma after mogamulizumab monotherapy., PMID:38770705
[Drug-related exanthema under immunotherapy and targeted oncological therapy]., PMID:38772932
[Side effects of dermato-oncologic therapies]., PMID:38802653
A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments., PMID:38804300
Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4-positive peripheral T-cell lymphoma and relapsed or refractory cutaneous T-cell lymphoma: A post-marketing surveillance in Japan., PMID:38847317
Macrophage-derived chemokine CCL22 establishes local LN-mediated adaptive thermogenesis and energy expenditure., PMID:38924414
Chemokines and Cytokines in Immunotherapy of Melanoma and Other Tumors: From Biomarkers to Therapeutic Targets., PMID:38928238
Immune-related adverse events associated with mogamulizumab: a comprehensive review of the literature., PMID:38990648
Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study., PMID:39007062
CCL17, CCL22 and their receptor CCR4 in hematologic malignancies., PMID:39240278
Chemokine receptors in COVID-19 infection., PMID:39260938
Phenotypic profiling of human induced regulatory T cells at early differentiation: insights into distinct immunosuppressive potential., PMID:39264416
Mogamulizumab and Concomitant Hypofractionated Low-Dose Total Skin Electron Beam Therapy (2 × 4 Gy) in Cutaneous T-Cell Lymphoma: Proof of Principle, Report of Two Cases., PMID:39330028
Improved survival among elderly patients with aggressive adult T-cell leukemia/lymphoma: Impact of mogamulizumab-containing chemotherapy., PMID:39390209
CCR4+Tfh2 cells specifically produce IL-4 driving the pathological reaction in IgG4-related disease., PMID:39625839
The FGFR inhibitor Rogaratinib reduces microglia reactivity and synaptic loss in TBI., PMID:39635532
Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy., PMID:39701282
Practical recommendations for therapy and monitoring of mogamulizumab patients in Germany., PMID:39723687
Targeted antibody therapy as a treatment strategy for aggressive adult T-cell leukemia/lymphoma., PMID:39827571
LuQi formula ameliorates pressure overload-induced heart failure by regulating macrophages and regulatory T cells., PMID:40118747
Phase I study on neoadjuvant combination immunotherapy with mogamulizumab and nivolumab for solid tumors., PMID:40180420
A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia/Lymphoma., PMID:40373281
Biological and Clinical Relevance of Genetic Alterations in Peripheral T-cell Lymphomas., PMID:40416001
Frequency and stability of populations of CD4+ and CD4+CD25+Foxp3+CD127lo Treg in healthy adults defined by cytometry using monoclonal antibodies to T cell associated molecules., PMID:40464367
First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors., PMID:40536766
For research use only. Not for human or drug use.
